Elena Elimova, MD, on PD-L1 Subgroup Analysis From HERIZON-GEA-01

June 04, 2026 By The ASCO Post Staff

Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).

Related Content